In planta expression of nanobody-based designer chicken antibodies targeting Campylobacter

PLoS One. 2018 Sep 27;13(9):e0204222. doi: 10.1371/journal.pone.0204222. eCollection 2018.

Abstract

Campylobacteriosis is a widespread infectious disease, leading to a major health and economic burden. Chickens are considered as the most common infection source for humans. Campylobacter mainly multiplies in the mucus layer of their caeca. No effective control measures are currently available, but passive immunisation of chickens with pathogen-specific maternal IgY antibodies, present in egg yolk of immunised chickens, reduces Campylobacter colonisation. To explore this strategy further, anti-Campylobacter nanobodies, directed against the flagella and major outer membrane proteins, were fused to the constant domains of chicken IgA and IgY, combining the benefits of nanobodies and the effector functions of the Fc-domains. The designer chimeric antibodies were effectively produced in leaves of Nicotiana benthamiana and seeds of Arabidopsis thaliana. Stable expression of the chimeric antibodies in seeds resulted in production levels between 1% and 8% of the total soluble protein. These in planta produced antibodies do not only bind to their purified antigens but also to Campylobacter bacterial cells. In addition, the anti-flagellin chimeric antibodies are reducing the motility of Campylobacter bacteria. These antibody-containing Arabidopsis seeds can be tested for oral passive immunisation of chickens and, if effective, the chimeric antibodies can be produced in crop seeds.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Bacterial / immunology
  • Antibodies, Bacterial / metabolism*
  • Arabidopsis / genetics
  • Arabidopsis / metabolism
  • Bacterial Outer Membrane Proteins / genetics
  • Bacterial Outer Membrane Proteins / immunology
  • Campylobacter / immunology*
  • Campylobacter / physiology
  • Campylobacter Infections / immunology
  • Campylobacter Infections / prevention & control
  • Campylobacter Infections / veterinary
  • Chickens
  • Flagella / genetics
  • Flagella / immunology
  • Flagellin / immunology
  • Immunity, Maternally-Acquired
  • Immunoglobulin A / genetics
  • Immunoglobulin A / metabolism
  • Immunoglobulins / genetics
  • Immunoglobulins / metabolism
  • Nicotiana / genetics
  • Nicotiana / metabolism
  • Plants, Genetically Modified / metabolism*
  • Poultry Diseases / immunology
  • Poultry Diseases / prevention & control
  • Recombinant Fusion Proteins / immunology
  • Recombinant Fusion Proteins / metabolism*
  • Single-Domain Antibodies / immunology
  • Single-Domain Antibodies / metabolism*

Substances

  • Antibodies, Bacterial
  • Bacterial Outer Membrane Proteins
  • IgY
  • Immunoglobulin A
  • Immunoglobulins
  • Recombinant Fusion Proteins
  • Single-Domain Antibodies
  • Flagellin

Grants and funding

The research that yielded these results, was funded by the Belgian Federal Public Service of Health, Food Chain Safety and Environment (www.health.belgium.be) through the contract RF 13/6272 CampyNanoCure. The funding was received by HDG, JPH, FP, AM and FH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.